HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.

AbstractOBJECTIVE:
To assess the reliability of the TAS/ecarin clotting time (ECT) for on-line monitoring of r-hirudin in cardiovascular surgery with and without cardiopulmonary bypass (CPB).
DESIGN:
Samples were spiked with r-hirudin (0 to 5 microg/mL) and calibration curves constructed. Reproducibility was evaluated by measurement of the sample five times at each concentration. The influence of variations in hematocrit, plasma factors, and platelet count on the test results was examined. Samples were obtained from patients during cardiovascular surgery with CPB (n = 8), without CPB (n = 3), and from volunteers (n = 5) and compared with the laboratory reference tests. All tests were performed in duplicate.
SETTING:
Deutsches Herzzentrum Berlin.
PARTICIPANTS:
Five healthy volunteers and 11 patients undergoing cardiovascular surgery.
INTERVENTIONS:
None.
MEASUREMENTS AND MAIN RESULTS:
The TAS/ECT showed linearity and reliability to an r-hirudin concentration of 5 microg/mL and was not influenced (p < 0.005) by the varying conditions of the in vitro setup. The correlation to the laboratory method was 0.74 for the CPB group and 0.87 for the non-CPB group.
CONCLUSIONS:
The TAS/ECT is a reliable assay for monitoring r-hirudin at the point of care. With this information, the use of r-hirudin during surgery or angioplasty should become more effective and safer.
AuthorsA Koster, R Hansen, O Grauhan, H Hausmann, M Bauer, R Hetzer, H Kuppe, F Mertzlufft
JournalJournal of cardiothoracic and vascular anesthesia (J Cardiothorac Vasc Anesth) Vol. 14 Issue 3 Pg. 249-52 (Jun 2000) ISSN: 1053-0770 [Print] United States
PMID10890474 (Publication Type: Journal Article)
Chemical References
  • Anticoagulants
  • Hirudins
  • Recombinant Proteins
  • Heparin
Topics
  • Adult
  • Aged
  • Anticoagulants (blood)
  • Cardiopulmonary Bypass
  • Drug Monitoring
  • Female
  • Heparin (adverse effects)
  • Hirudins (blood)
  • Humans
  • Male
  • Middle Aged
  • Recombinant Proteins (blood)
  • Reproducibility of Results
  • Thrombocytopenia (chemically induced)
  • Whole Blood Coagulation Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: